Lipoprotein-Associated Phospholipase A ₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial

This publication has 35 references indexed in Scilit:

• Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma
  Clinical Chemistry, 2005
• Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis
  Atherosclerosis, 2005
• Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada
  Circulation, 2005
• The effect of statin therapy on lipoprotein associated phospholipase A2 levels
  Atherosclerosis, 2005
• Effects of Atorvastatin Versus Other Statins on Fasting and Postprandial C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Patients With Coronary Heart Disease Versus Control Subjects
  The American Journal of Cardiology, 2005
• Association of Lipoprotein-Associated Phospholipase A ₂ Mass and Activity With Calcified Coronary Plaque in Young Adults
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
• Markers of Inflammation and Cardiovascular Disease
  Circulation, 2003
• Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in Plasma
  Biochemical and Biophysical Research Communications, 1999
• Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
• Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction
  Coronary Artery Disease, 1993